Therapy with SR18662 significantly reduces expansion and proliferation of CRC cells. SR18662 exhibits improved efficacy in minimizing viability of several CRC mobile traces. Flow cytometry Assessment adhering to SR18662 treatment shows an increase in cells captured in possibly S or G2/M phases in the mobile cycle and a major increase in the quantit